Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Proposed FDA nanotech programme would develop best practices for industry

This article was originally published in Clinica

Executive Summary

The FDA’s National Center for Toxicological Research (NCTR) would be the “ideal candidate” for studying the safety of nanotech materials used in medical devices, drugs and biologics, Senator Mark Pryor said on introducing legislation into Congress on nanotech safety.